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Strategies to prevent neuronal damage in pediatric bacterial
meningitis
Denis Grandgirard and Stephen L. Leib
Purpose of review
The mortality of bacterial meningitis can reach 30%, and
up to 50% of survivors suffer from persisting neurological
deficits as a consequence of the disease. The incidence
of neurological sequelae of bacterial meningitis has not
improved over the last decade. Adjunctive therapeutic
options are limited, and ongoing research into the
pathophysiology of brain damage in bacterial meningitis
aims at providing the scientific basis for future
development of more efficient adjunctive options.
Recent findings
In a population with good access to health care,
dexamethasone given before or at the time of initiation of
antibiotic therapy acts beneficially in pediatric
pneumococcal meningitis, but not in meningococcal
meningitis. In experimental animal models, brain-derived
neurotrophic factor protected against brain injury and
improved hearing while melatonin, which has antioxidant
properties among other effects, reduced neuronal death.
Transgene technology can be used to provide new
insights into the pathophysiology of the disease and to
identify potential therapeutic targets.
Summary
Although dexamethasone improves outcome of bacterial
meningitis under defined circumstances, the morbidity of
bacterial meningitis still remains unacceptably high.
Experimental models may help to identify new therapeutic
strategies to further improve the neurological outcome in
young children suffering from bacterial meningitis.
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Introduction
Bacterial meningitis, and in particular meningitis of chil-
dren, is associated with devastating mortality rates of up
to 30%. Moreover, 20–50 % of pediatric patients who
survive the infection have serious and permanent neu-
rological sequelae, which include deafness, mental retar-
dation and learning impairment, sensory-motor deficits,
seizure disorders and cerebral palsy. The incidence of
neurologic sequelae of bacterial meningitis in children
has not significantly improved over the last decade [1].
For example, comparison of two timely distinct national
prospective studies performed in England and Wales
showed a decrease in the acute phase mortality from
22% in the time period from 1985 to 1987 to 6.6% in
the time period from 1996 to 1997. In contrast, the cor-
responding follow-up studies on the incidence of serious
disabilities in the surviving patients showed an inci-
dence of 25.5% in the time period from 1985 to 1987
and an incidence of 23.5% in the time period from
1996 to 1997. Compared with general practice or hospi-
tal control patients, children that survived bacterial
meningitis had a fourfold to 16-fold increase in the risk
of developing severe disabilities [2•]. Even 12 years
after the disease, survivors of meningitis are at greater
risk of deficits in intellectual, academic and executive
ability than grade-matched and gender-matched con-
trols. As a consequence, children after meningitis are
more than twice as likely as controls to require special
educational assistance (27.0% compared with 12.5%). A
younger age at illness is associated with a poorer effi-
ciency in performing linguistic and executive functions,
and may suggest that cerebral insult may have a greater
impact on a developing brain [3•]. Group B streptococ-
cus (GBS) is the most common etiological agent in neo-
nates and Streptococcus pneumoniae and Neisseria meningi-
tidis are the most common causes of bacterial meningitis
in infants and young children worldwide [4••]. Pneumo-
coccal meningitis is consistently associated with a parti-
cularly high incidence of neurological sequelae, with up
to half of the survivors presenting some form of neuro-
logical deficits [5,6]. A retrospective study of 49 patients
admitted in a single pediatric intensive care unit
between 1990 and 2002 in France and diagnosed with
pneumococcal meningitis recorded a mortality rate of
49% and neurological impairment in 48% of patients dis-
charged from the hospital with a mean follow-up of 5
years (range 1–12 years) [7•].
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Brain injury caused by bacterial meningitis prominently
affects three brain structures, namely the cortex, the
hippocampus and the inner ear. As shown in pathologic
studies in patients dying from bacterial meningitis and
in corresponding animal models, the cortical regions of
the brain display areas of acute neuronal injury asso-
ciated with areas of focal ischemic necrosis [8]. In the
hippocampus, apoptotic damage occurs in the inner
blade of the dentate gyrus and this damage has been
associated with impairment of learning and memory in
experimental models of pneumococcal meningitis [9,10].
The vulnerable cells in the dentate gyrus have been
identified to include immature neurons recently gener-
ated from stem cells [11]. Necrotic cell death is also
observed in the CA1–CA4 sectors of the hippocampus,
and in the dentate gyrus, particularly in adult mice,
when the damage is severe [12]. A different form of hip-
pocampal damage characterized by clusters of shrunken
and pyknotic nuclei affects cells spanning the entire
blade of the dentate gyrus in newborn rats infected
with GBS [11].
Hearing impairment is the most common neurological
sequel following meningitis and is observed in up to
30% of patients, depending on the infecting pathogen
[13–15]. In an adult rat model of pneumococcal menin-
gitis the severity of permanent hearing impairment
assessed two weeks after the infection correlated signif-
icantly with the loss of type I spiral ganglion neurons
[16]. Thus neuronal loss in the spinal ganglion repre-
sents a histomorphological correlate of hearing impair-
ment.
In the time period covered in this review (11/2004 to
9/2005), a number of pathogenetic factors have been
evaluated for their contribution to the development of
brain damage in bacterial meningitis. Matrix-metallopro-
teinases (MMP) have been shown to facilitate the extra-
vasation of white blood cells (WBCs) and to participate
in blood–brain barrier disruption by degrading compo-
nents of the basal lamina of the cerebral vasculature
[17•]. The presence of reactive oxygen species and reac-
tive nitrogen species leads to the production of peroxi-
nitrite and the occurrence of lipid peroxidation, as
observed in inflammatory cells and penetrating cortical
blood vessels in brain specimens from patients [18]. In
addition, oxidants have been shown to induce DNA
strand breakage and subsequent poly(ADP ribose) poly-
merase activation, initiating an energy-consuming intra-
cellular cycle that ultimately leads to cellular energy
depletion and death, specifically in endothelial cells of
the cerebral vasculature [19]. Finally, sustained cytokine
production, especially IL-1β, has been shown to corre-
late with adverse disease outcome and/or severity of dis-
ease [20].
Factors found to contribute to ischemic injury include
the production of vasoconstrictive endothelins, the acti-
vation of platelets and the induction of a procoagulant
state [21].
Different bacterial toxins have been shown to directly
trigger the host apoptotic machinery: S. pneumoniae-
produced pneumolysin and hydrogen peroxide have
been shown to exert neurotoxicity in vitro and in an
experimental model of pneumococcal meningitis [22].
Hemolysin may play a role during GBS meningitis,
since it has been shown to induce apoptosis [23].
Strategies for preventing neuronal damage
during bacterial meningitis: current concepts
In the time period covered by this review (11/2004 to
9/2005) the pathogenetic mechanisms identified as tar-
gets for adjuvant therapy include the following:
(1) bacterial killing and the prevention of associated
release of bacterial components [24••,25,26•,27•];
(2) the host mechanisms for recognition of bacteria or
bacterial components and the initiation of the
inflammatory reaction [28•,29•,30,31•,32•,33•,34•,35];
(3) the modulation of the inflammatory reaction by
adjuvant therapy with dexamethasone [4••,7•,36••,
37,38•,39•,40•];
(4) the inhibition of inflammatory and/or neurotoxic
mediators [41,42•,43•,44,45•,46••];
(5) the modulation of apoptotic pathways [47,48•,49•,
50•].
Bacterial killing and the prevention of associated
release of bacterial components
Bacteria and their components engage the innate
immune response through activation of the members
of Toll-like receptors (TLRs), including TLR2 and
TLR4. Antibiotic therapy reduces the overall release
of these components, when compared to unhindered
replication and subsequent autolysis. Bacteriolytic anti-
biotics, however, have been shown to induce an initial
brisk release of bacterial components that may accentu-
ate inflammation. The use of antibiotics that inhibit
RNA/protein synthesis or DNA replication (rifamycins,
macrolides, clindamycin, ketolides and quinolones)
reduces bacterial lysis [24••]. For example, the produc-
tion of inflammatory mediators by murine macrophages
is decreased when stimulated by GBS exposed to rifam-
pin or clindamycin compared with ampicillin or cefotax-
ime [25]. Rifampicin, given 6 hours prior to ceftriaxone,
reduced the release of bacterial components into the
cerebrospinal fluid (CSF) and attenuated neuronal
injury in the hippocampus [51]. Similarly, clindamycin
lowered extracellular concentration of hydroxyl radicals
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and glutamate, and decreased neuronal apoptosis in the
dentate gyrus in a rabbit model of pneumococcal menin-
gitis [26•]. The cyclic lipopeptide daptomycin kills bac-
teria by inducing a rapid depolarization of the bacterial
membrane without subsequent disruption and has been
suggested as a candidate for the treatment of gram-posi-
tive bacterial meningitis [27•].
Recognition of bacterial components and the initiation
of the inflammatory reaction
The brain’s inflammatory response to bacterial infection
determines the outcome of bacterial meningitis, that is,
the extent of brain injury as a consequence of the dis-
ease. Thus, adjuvant therapeutic strategies include tar-
geting the inflammatory reaction as early and as
upstream as possible. Early events in the inflammatory
cascade are the recognition of the pathogens, the result-
ing immune activation, the recruitment of WBCs in the
CSF and the release of inflammatory mediators into the
subarachnoid space. Therapeutic strategies developed
with this aim strive to leave the beneficial components
of inflammation in place, but to attenuate the harmful
ones (reviewed in [23]).
Recent data generated in experimental models concern
the recognition of the pathogen and the initiation of the
immune reaction. CD14 myeloid receptor, TLRs and
MyD88 have all been implicated in immune activation.
CD14-/- mice showed a higher mortality from infection
by S. pneumoniae whereas the systemic host defence and
the CSF bacterial clearance were not affected. The
authors suggested, however, that CD14 deficiency
leads to a stronger neutrophil recruitment into the CSF
and an excessive meningeal inflammation [29•].
TLR2 is involved in the recognition of gram-positive
pathogens. TLR2 deficiency leads to an increased sever-
ity of the disease and earlier mortality in murine models
of pneumococcal meningitis. A stronger accumulation of
bacteria in the ventricules and the meninges has also
been observed. A delay in granulocyte recruitment and
a weakened antimicrobial capacity are believed to con-
tribute to the failing host response in TLR2 deficient
mice [52]. TLR2 has also been recently suggested to
play a role in the regulation of TNF-alpha gene expres-
sion in the brain during pneumococcal meningitis;
TLR2 deficiency is associated with enhanced TNF
gene expression in the brain [30].
MyD88, which acts downstream of TLR2, is necessary
to mount a robust immune response to S. pneumoniae in
the central nervous system. In transgenic animals lack-
ing MyD88, a marked reduction of CSF pleocytosis and
a decreased expression of cytokines and chemokines
were observed. MyD88 deficiency, however, was asso-
ciated with a worsening of the clinical disease, owing
to a more severe bacteremia and an enhanced expression
of TNF-alpha in the lungs [34•].
The hypothesis that avoiding leukocyte recruitment in
the CSF in order to decrease the local inflammatory
reaction, which would then be beneficial, has recently
been challenged by Brandt et al. [31•]. For example,
treatment with Fucoidin initiated at the time of infec-
tion in experimental pneumococcal meningitis led to a
higher mortality, but had no measurable effect on brain
damage or bacterial numbers in the CSF compartment.
The highest mortality was associated with an increase in
the numbers of bacteria in the blood, suggesting that
leukocyte blockade affected the host’s ability to control
systemic but not central nervous system infection. This
hypothesis was supported by the observation that the
boosting of the peripheral neutrophil count by pre-
treatment with granulocyte-colony-stimulating factor
(G-CSF) reduced mortality and prevented brain
damage, and led to reduced numbers of bacteria in the
blood and the CSF [33•]. Thus, the degree of systemic
infection and the severity of brain damage are likely to
contribute independently to mortality. This hypothesis
may be supported by the apparent discrepancies
between the previously mentioned study of Brandt and
a recent study that reported the reduction of leukocyte
influx by treatment with a tyrosine kinase inhibitor (tyr-
phostin AG126). This study [32•] in pneumococcal-cell-
wall-induced meningitis showed that the attenuation of
CSF-pleocytosis reduced the increases in blood flow and
intracranial pressure.
Fas (CD95) and Fas ligand (FasL, CD95L) have been
shown to be involved in the acute inflammatory
response by attracting neutrophils and regulating their
survival [53,54]. Increased levels of soluble Fas and
FasL have been found in CSF of patients with bacterial
meningitis. Recent data generated in experimental mod-
els using transgenic animals that lack Fas and FasL,
however, could not find a contribution of Fas/FasL in
the regulation of inflammatory response during pneumo-
coccal meningitis [35].
From the data generated in the reviewed period one
might conclude that a higher neutrophil count before
the initiation of antibiotic therapy is beneficial to limit
the spread of infection and the development of severe
bacteremia. Once antibiotic therapy has been initiated,
however, the contribution of neutrophils to bacterial
clearance in the CSF seems small and pales in compar-
ison to the detrimental effect of high CSF pleocytosis on
brain tissue.
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Modulation of the inflammatory reaction by adjuvant
therapy with dexamethasone
Given the contribution of excessive inflammation to the
development of brain damage in bacterial meningitis,
anti-inflammatory adjuvant treatment with dexametha-
sone has been tested in several controlled clinical trials.
Addressing a complete and critical overview on this
topic goes beyond the scope of this review, but has
been recently done by others [36••,55••,56••]. For
meningococcal meningitis, dexamethasone was not pro-
ven to be effective in decreasing sequelae among pedia-
tric patients in a recent study performed in Brazil [40•].
Another recent retrospective population-based study
performed in Sydney (1994–1999) in childhood pneumo-
coccal meningitis demonstrated that, in a population
with good access to health care, early recognition of
pneumococcal meningitis and treatment with adjunctive
dexamethasone significantly improved mortality and
severe disabilities in survivors [39•]. In another study
performed in a pediatric intensive care unit in France
[7•], dexamethasone treatment did not influence in-hos-
pital death in a multivariate analysis; however, the ben-
eficial effect may have been reduced by the delay
between antibiotic and steroid administration and the
selection of a high-severity population (49% mortality).
Experimental studies on the use of adjunctive dexa-
methasone have generated conflicting data. Whereas
dexamethasone treatment was shown to increase both
acute hippocampal injury and long-term learning defi-
cits in an infant rat model [57], it decreased neurological
sequelae and caspase activity in an adult rat model [37].
The measured outcomes, however, were different in
these two studies (hippocampal injury in the first, cas-
pase activity in the cerebellum in the second study), as
well as the protocol for assessment of learning capacity;
a direct comparison is therefore not possible.
Inhibition of inflammatory and/or neurotoxic mediators
Gene knockout technology combined with experimental
meningitis in mice has been used to investigate the role
of inflammation in the development of brain injury.
This has been recently reviewed by Paul et al. [46••].
In TNF-α knockout mice, mortality and spatial memory
deficits were increased in ceftriaxone-treated experi-
mental pneumococcal meningitis [41]. TNF-α has
been shown, however, to participate in postmeningitic
hearing loss, which was reduced by blockade with neu-
tralizing antibodies in a Mongolian gerbil model [44].
Few other selective intervention strategies have been
directed against specific cytokines so far, and ongoing
research focuses on the pattern and kinetic of cytokine
expression during bacterial meningitis [45•]. Thus a
deeper understanding of the role of the various media-
tors in the inflammatory network is a prerequisite for the
development of individual targets for adjuvant therapy.
A number of strategies have been evaluated in infant
models of bacterial meningitis, which, until now, have
not been translated into clinical use (see Table 1). One
main challenge seems to be the difficulty in finding
therapies that are able to attenuate both hippocampal
and cortical damage in bacterial meningitis. For exam-
ple, experimental therapies using metalloproteinase
inhibitors are generally protective against cortical
damage. Furthermore, MMP-inhibition combined with
inhibition of TNF-α converting enzyme (TACE) inhibi-
tory activity has been shown in one study to also protect
from hippocampal dentate gyrus injury. The beneficial
effect on both forms of injury by an MMP/TACE inhi-
bitor, however, was restricted to one compound and
could not be shown for other similar MMP/TACE inhi-
bitors. Thus the beneficial effect of MMP/TACE inhi-
bition may not directly depend on the TACE inhibitory
activity [42•,58,59]. Antioxidant therapy has been shown
to protect the neocortex from damage, but not from hip-
pocampal apoptosis. The beneficial effect on cortical
injury may be attributed to a protective effect on the
cerebral microvasculature leading to an amelioration of
cerebral perfusion [60]. Recently, the continuous admin-
istration of melatonin in a model of ceftriaxone-treated
pneumococcal meningitis in rabbit has been shown to
decrease hippocampal apoptosis. Whether the observed
effect was due to the radical scavenging properties of
melatonin or to its influence on neurotrophic factors’
expression remains to be clarified [43•].
Modulation of apoptotic pathways
Caspase inhibitors have been previously shown to attenu-
ate hippocampal apoptosis in the dentate gyrus. While
the beneficial effect of the pan-caspase inhibitor z-
VAD-fmk could be attributed to the down-modulation
of the inflammatory response and associated reduction
of caspase inhibition [61], the specific inhibition of cas-
pase-3 with Ac-DEVD-CHO relied solely on the interfer-
ence with the apoptotic pathway [62]. Recently, it has
been suggested that two phases of apoptosis were dis-
cernible. Neuronal injury at 18 h after infection was inde-
pendent of the caspase-3 pathway, and neuronal cell
death at 24 h after infection was attenuated in the
absence of the caspase-3 pathway [47]. Pharmacological
interventions aimed at increasing the survival rate of neu-
rons in pediatric patients with meningitis will therefore
need to take the kinetic aspects of the development of
brain damage into account. Administration of exogenous
brain-derived neurotrophic factor (BDNF) has been
shown to attenuate all forms of brain damage associated
with pneumococcal and GBS meningitis [48•]. The ther-
apeutic strategy of exogenous BDNF administration has
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been further supported by the finding that expression of
endogenous BDNF was found to be decreased by anti-
biotic treatment in experimental pneumococcal meningi-
tis [63]. Furthermore, BDNF exerted a protective effect
on hearing capacity in experimental pneumococcal
meningitis [49•]. Thus, BDNF has been shown to mod-
ulate caspase-dependent and independent pathways of
neuronal damage, but its mechanism of action is still
poorly understood.
A new mechanism to trigger apoptosis has recently been
proposed [50•]. S. pneumoniae was shown to inhibit phos-
phatidylcholine biosynthesis, presumably by the pneu-
mococcal toxins pneumolysin and/or H2O2. The inhibi-
tion of this pathway causes apoptosis in a variety of brain
cells in vitro. In a mouse model of pneumococcal menin-
gitis, hippocampal damage was prevented by treatment
with cytidine diphosphocholine.
Summary
To date, there is no ideal adjunctive therapy for the
treatment of bacterial meningitis in all patient popula-
tions. The available evidence thus far supports the use
of dexamethasone, when given before or together with
the first dose of antibiotics, in children and adults with
pneumococcal or haemophilus meningitis. Dexametha-
sone is not recommended for the treatment of meningo-
coccal, gram-negative bacillary meningitis or for bacter-
ial meningitis in neonates [36••]. Future research into
antibiotic therapy for bacterial meningitis may focus on
limiting the release of bacterial components, provided
that a sufficiently rapid CSF sterilization can be
achieved. Modulation of individual components of the
inflammation cascade may be evaluated while cautiously
keeping an eye on the systemic effects. This was exem-
plified by studies on leukocyte recruitment, where a
decrease in CSF inflammatory parameters and brain
damage did not contribute to a better outcome owing
to an increase in severity of the systemic disease. Such
‘double-edged swords’ are probably hidden in a number
of targets currently investigated as adjunctive strategies.
The complex network of cytokines, chemokines, their
receptors and other inflammatory mediators that partici-
pate in CSF inflammation will require more studies
before a rational neuroprotection strategy can be devel-
oped. Finding a uniform target for adjunctive therapy is
further hampered by the different pathophysiologic
pathways that lead to the distinct forms of brain damage
in bacterial meningitis, that is, necrosis in the cortex,
hippocampal apoptosis and damage to the inner ear.
Finally, meningitis in neonates, children and adults
may need to be considered separately. Future research
may therefore include the differences in the pathophy-
siology of brain damage that arises from meningitis
caused by different pathogens and in defined patient
populations.
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Table 1 Therapeutic interventions in the infant rat models and their effect on cortical and hippocampal injury, as well as
survival (partially adapted from [21,64]). Only new findings covering the period of the review are referenced
Intervention Compound Pathogen
Neuronal injury
Mortality
Recent
referencesCortex Hippocampus
iNOS inhibition Aminoguanidine GBS increase ND ND
Endothelin agonist Bosentan SP decrease no change no change
Antioxidants PBN SP decrease increase no change
GBS decrease decreasea ND
NAC SP decrease no change no change
DFO SP decrease no change no change
TLM SP decrease no change decrease
MMP inhibition GM-6001 SP decrease ND ND
MMP + TACE inhibition BB-1101 SP decrease decrease decrease
TNF484 SP decrease non change no change [42•]
TNF-α neutralization Neutralizing Ab GBS no change decreasea decreaseb
Attenuation of inflammation Dexamethasone SP ND increase no change
GBS decrease ND no change
Caspase inhibition Ac-DEVD-CHO SP ND decrease ND
Neurotrophin BDNF SP ND decrease no change [48•]
GBS decrease decreasea no change
Glutamate antagonist Kynurenic acid GBS decrease decreasea ND
iNOS: inducible nitric oxide synthase; PBN: α-phenyl-butyl nitrone; NAC: N-acetylcysteine; DFO: deferoxamine; TLM: trylizad-mesylate; SP:
Streptococcus pneumoniae; ND: not determined.
aDamage in the dentate gyrus of the hippocampus consisting of pyknotic cells, distinct from caspase-dependent apoptosis.
bOnly when neutralizing antibodies were given systemically, and not intracisternally.
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